722 related articles for article (PubMed ID: 33325008)
21. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
22. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
Bradley CL; McMillin SM; Hwang AY; Sherrill CH
Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
[TBL] [Abstract][Full Text] [Related]
23. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.
Bucheit J; Ayers J; Pamulapati L; Browning A; Sisson E
J Cardiovasc Pharmacol; 2022 Aug; 80(2):171-179. PubMed ID: 35767712
[TBL] [Abstract][Full Text] [Related]
24. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond.
Dutta P; Kumar Y; Babu AT; Giri Ravindran S; Salam A; Rai B; Baskar A; Dhawan A; Jomy M
Cureus; 2023 May; 15(5):e38379. PubMed ID: 37265914
[TBL] [Abstract][Full Text] [Related]
25. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program.
Frías JP
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):111-130. PubMed ID: 36908082
[TBL] [Abstract][Full Text] [Related]
26. Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.
Bulum T
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289848
[TBL] [Abstract][Full Text] [Related]
27. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
Scheen AJ
Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119
[TBL] [Abstract][Full Text] [Related]
28. Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin.
Fanshier AV; Crews BK; Garrett MC; Johnson JL
Clin Diabetes; 2023; 41(3):367-377. PubMed ID: 37456095
[TBL] [Abstract][Full Text] [Related]
29. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS; Douros JD; Gabe MB; Showalter AD; Wainscott DB; Suter TM; Capozzi ME; van der Velden WJ; Stutsman C; Cardona GR; Urva S; Emmerson PJ; Holst JJ; D'Alessio DA; Coghlan MP; Rosenkilde MM; Campbell JE; Sloop KW
JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32730231
[TBL] [Abstract][Full Text] [Related]
30. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
Scheen AJ; Radermecker RP; Paquot N
Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
[TBL] [Abstract][Full Text] [Related]
31. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Gallwitz B
Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
[TBL] [Abstract][Full Text] [Related]
32. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.
Andraos J; Muhar H; Smith SR
Rev Endocr Metab Disord; 2023 Dec; 24(6):1089-1101. PubMed ID: 37526853
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Zhou Q; Lei X; Fu S; Liu P; Long C; Wang Y; Li Z; Xie Q; Chen Q
Diabetol Metab Syndr; 2023 Oct; 15(1):222. PubMed ID: 37904255
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
35. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.
Stefanou MI; Theodorou A; Malhotra K; Aguiar de Sousa D; Katan M; Palaiodimou L; Katsanos AH; Koutroulou I; Lambadiari V; Lemmens R; Giannopoulos S; Alexandrov AV; Siasos G; Tsivgoulis G
Eur Stroke J; 2024 Feb; ():23969873241234238. PubMed ID: 38400569
[TBL] [Abstract][Full Text] [Related]
36. Tirzepatide for type 2 diabetes.
Anderson SL; Marrs JC
Drugs Context; 2023; 12():. PubMed ID: 37664792
[TBL] [Abstract][Full Text] [Related]
37. The
Lempesis IG; Liu J; Dalamaga M
Metabol Open; 2022 Dec; 16():100220. PubMed ID: 36530219
[TBL] [Abstract][Full Text] [Related]
38. Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
Razzaki TS; Weiner A; Shukla AP
Ther Clin Risk Manag; 2022; 18():955-964. PubMed ID: 36199834
[TBL] [Abstract][Full Text] [Related]
39. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
40. How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms RJ; Coghlan MP; Sloop KW
Trends Endocrinol Metab; 2020 Jun; 31(6):410-421. PubMed ID: 32396843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
